Proceedings of the 13th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2026
Vol. 5 No. s1 (2026)
Mortality following major gastrointestinal bleeding among patients receiving direct oral anticoagulants
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 16 April 2026
0
Views
0
Downloads
Authors
Direct oral anticoagulants (DOACs) are increasingly used for the treatment of cancer-associated venous thromboembolism (CAT). However, concerns remain regarding bleeding complications, particularly gastrointestinal (GI) bleeding, and their associated morbidity and mortality in patients with cancer. This narrative review summarizes available evidence on the epidemiology, predictors, mortality, and management of DOAC-associated major GI bleeding in this high-risk population. Across randomized controlled trials, major bleeding rates with DOACs range from 4 to 7%, with GI bleeding accounting for much of the observed excess bleeding, compared with low molecular weight heparin (LMWH), particularly among patients with unresected upper GI cancers. Observational studies in the cancer population confirm that GI bleeding is the predominant site of major bleeding complications, and it is associated with substantial 30-day mortality rates of 10-20%. Evidence to guide anticoagulation resumption after GI bleeding in patients with cancer is limited. Available data suggest that resumption of anticoagulation reduces thromboembolic events and all-cause mortality at the cost of increased recurrent bleeding risk, with early resumption associated with the highest rates of rebleeding events. In conclusion, GI bleeding is a frequent and clinically important complication of DOAC therapy in patients with cancer, highlighting the importance of individualized, multidisciplinary, and patient-centered management strategies.
Downloads
Download data is not yet available.
Citations
1. Bertoletti L, Madridano O, Jimenez D, et al. Cancer-Associated thrombosis: trends in clinical features, treatment, and outcomes from 2001 to 2020. JACC CardioOncol 2023;5:758-72. DOI: https://doi.org/10.1016/j.jaccao.2023.09.003
2. Carrier M, Cameron C, Delluc A, et al. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res 2014;134:1214-9. DOI: https://doi.org/10.1016/j.thromres.2014.09.039
3. Frere C, Farge D, Schrag D, et al. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol 2022;15:69. DOI: https://doi.org/10.1186/s13045-022-01289-1
4. Petit B, Soudet S, Poenou G, et al. Cancer-associated thrombosis: How many patients seen in clinical practice would be eligible for a direct oral anticoagulant randomized controlled trial? Respir Med Res 2023;85:101069. DOI: https://doi.org/10.1016/j.resmer.2023.101069
5. Khan F, Tritschler T, Marx CE, et al. Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis. Eur Heart J 2025:ehaf453. Online Ahead of Print. DOI: https://doi.org/10.1093/eurheartj/ehaf453
6. Lloyd AJ, Dewilde S, Noble S, et al. What Impact does venous thromboembolism and bleeding have on cancer patients' quality of life? Value Health 2018;21:449-55. DOI: https://doi.org/10.1016/j.jval.2017.09.015
7. Little D, Chai-Adisaksopha C, Hillis C, et al. Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: A systematic review and meta-analysis. Thromb Res 2019;175:102-9. DOI: https://doi.org/10.1016/j.thromres.2019.01.020
8. Monreal M, Falga C, Valdes M, et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006;4:1950-6. DOI: https://doi.org/10.1111/j.1538-7836.2006.02082.x
9. Abdulla A, Davis WM, Ratnaweera N, et al. A Meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer. Thromb Haemost 2020;120:702-13. DOI: https://doi.org/10.1055/s-0040-1708481
10. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018;378:615-24. DOI: https://doi.org/10.1056/NEJMoa1711948
11. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa Inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018;36:2017-23. DOI: https://doi.org/10.1200/JCO.2018.78.8034
12. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020;382:1599-607. DOI: https://doi.org/10.1056/NEJMoa1915103
13. Kraaijpoel N, Di Nisio M, Mulder FI, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE cancer study. Thromb Haemost 2018;118:1439-49. DOI: https://doi.org/10.1055/s-0038-1667001
14. Ageno W, Vedovati MC, Cohen A, et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thromb Haemost 2021;121:616-24. DOI: https://doi.org/10.1055/s-0040-1720975
15. Soff GA, Mones J, Wilkins C, et al. Rivaroxaban treatment of cancer-associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience. Res Pract Thromb Haemost 2019;3:349-56. DOI: https://doi.org/10.1002/rth2.12215
16. Nishimoto Y, Yamashita Y, Morimoto T, et al. Direct oral anticoagulant-associated bleeding complications in patients with gastrointestinal cancer and venous thromboembolism. Eur J Intern Med 2024;127:74-83. DOI: https://doi.org/10.1016/j.ejim.2024.04.012
17. Chornenki NLJ, Odabashian R, Carrier M, et al. All-cause mortality after major gastrointestinal bleeding among patients receiving direct oral anticoagulants: a systematic review and meta-analysis. Thromb Res 2025;252:109352. DOI: https://doi.org/10.1016/j.thromres.2025.109352
18. Mahmoud A, Luo S, Gage BF, et al. Association between anticoagulant-related bleeding and mortality in patients with solid tumors and cancer-associated venous thromboembolism. Am J Hematol 2025;100:535-8. DOI: https://doi.org/10.1002/ajh.27588
19. Wang TF, Luo S, Gage BF, et al. Association between anticoagulant-related bleeding and mortality in patients with hematological malignancies and cancer-associated venous thromboembolism. Thromb Res 2025;248:109284. DOI: https://doi.org/10.1016/j.thromres.2025.109284
20. Xu Y, Siegal DM. Anticoagulant-associated gastrointestinal bleeding: Framework for decisions about whether, when and how to resume anticoagulants. J Thromb Haemost 2021;19:2383-93. DOI: https://doi.org/10.1111/jth.15466
21. Majeed A, Wallvik N, Eriksson J, et al. Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. A risk modelling analysis. Thromb Haemost 2017;117491-9. DOI: https://doi.org/10.1160/TH16-07-0498
22. McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost 2020;18:411-21. DOI: https://doi.org/10.1111/jth.14662
23. Planquette B, Bertoletti L, Charles-Nelson A, et al. Rivaroxaban vs Dalteparin in cancer-associated thromboembolism: a randomized trial. Chest 2022;161:781-90. DOI: https://doi.org/10.1016/j.chest.2021.09.037
24. Schrag D, Uno H, Rosovsky R, et al. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in Patients with cancer: a randomized clinical trial. JAMA 2023;329:1924-33. DOI: https://doi.org/10.1001/jama.2023.7843
How to Cite
1.
Sharobim J, Wang T-F, Carrier M. Mortality following major gastrointestinal bleeding among patients receiving direct oral anticoagulants. Bleeding Thromb Vasc Biol [Internet]. 2026 Apr. 16 [cited 2026 Apr. 17];5(s1). Available from: https://www.btvb.org/btvb/article/view/432
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- Yishi Tan, Marc Carrier, Nicola Curry, Michael Desborough, Kathryn Musgrave, Marie Scully, Tzu-Fei Wang, Mari Thomas, Simon J. Stanworth, Cancer complicated by thrombosis and thrombocytopenia: still a therapeutic dilemma , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Kristen M. Sanfilippo, Tzu-Fei Wang, Venous thromboembolism and mortality in patients with hematological malignancies , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Marcello Di Nisio, Tzu-Fei Wang, Prediction and management of recurrent venous thromboembolism in patients with cancer , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Tzu-Fei Wang, Kristen M. Sanfilippo, Marc Carrier, Pharmacokinetic interactions between anticancer drugs and direct oral anticoagulants: clinical implications for safe anticoagulation , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
